Abstract
It has become increasingly clear that anti-tuberculosis regimens need optimization. Information gained using pharmacokinetics/ pharmacodynamics (PK/PD) methods in hollow fiber and animal model studies, in conjunction with Monte Carlo simulations, can be used to achieve this goal. PK/PD models of anti-tuberculosis drugs in hollow fibers, mice and guinea pigs have been remarkably concordant. Using exposures derived in these models it has been shown that the standard doses of pyrazinamide, rifampin, and ethambutol should be increased for a better efficacy, while doses of isoniazid need to be individualized. In addition, PK/PD driven doses have been proposed for new anti-tuberculosis agents such as moxifloxacin and PA-824.
Keywords: Mycobacterium tuberculosis, PK-PD, models, dosing schedule, dose optimization, bacteria, monotherapy, isoniazid, Fluoroquinolones, meningitis
Current Pharmaceutical Design
Title: In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Volume: 17 Issue: 27
Author(s): Shashikant Srivastava and Tawanda Gumbo
Affiliation:
Keywords: Mycobacterium tuberculosis, PK-PD, models, dosing schedule, dose optimization, bacteria, monotherapy, isoniazid, Fluoroquinolones, meningitis
Abstract: It has become increasingly clear that anti-tuberculosis regimens need optimization. Information gained using pharmacokinetics/ pharmacodynamics (PK/PD) methods in hollow fiber and animal model studies, in conjunction with Monte Carlo simulations, can be used to achieve this goal. PK/PD models of anti-tuberculosis drugs in hollow fibers, mice and guinea pigs have been remarkably concordant. Using exposures derived in these models it has been shown that the standard doses of pyrazinamide, rifampin, and ethambutol should be increased for a better efficacy, while doses of isoniazid need to be individualized. In addition, PK/PD driven doses have been proposed for new anti-tuberculosis agents such as moxifloxacin and PA-824.
Export Options
About this article
Cite this article as:
Srivastava Shashikant and Gumbo Tawanda, In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens, Current Pharmaceutical Design 2011; 17 (27) . https://dx.doi.org/10.2174/138161211797470192
DOI https://dx.doi.org/10.2174/138161211797470192 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Broad-spectrum Antimycobacterial Activities of Phenothiazines, In Vitro: Somewhere in All of this there May be Patentable Potentials
Recent Patents on Anti-Infective Drug Discovery Mechanism-Based Inactivation of Cytochrome P450 Enzymes: Chemical Mechanisms, Structure-Activity Relationships and Relationship to Clinical Drug-Drug Interactions and Idiosyncratic Adverse Drug Reactions
Current Drug Metabolism New Heterocyclic Hydrazones in the Search for Antitubercular Agents: Synthesis and In Vitro Evaluations
Letters in Drug Design & Discovery Withdrawal Notice: Highly Effective Synthesis of Dibromide of (+)-(1R, 2R)-and (-)-(1S, 2S)-1,2-diphenyl-1,2- ethylenediammonium (DPEN·2HBr) Assisted by Microwave
Current Green Chemistry Recent Complications and Issues in Tuberculosis Treatment
Recent Patents on Anti-Infective Drug Discovery New Strategy on Antimicrobial-resistance: Inhibitors of DNA Replication Enzymes
Current Medicinal Chemistry Iron Acquisition Pathways as Targets for Antitubercular Drugs
Current Medicinal Chemistry Sepsis and Solid Organ Transplantation
Current Drug Targets Withdrawal Notice: Community-wide Screening of Symptomatic and Asymptomatic Infection of Mycobacterium tuberculosis in the Saharia tribe of India
Combinatorial Chemistry & High Throughput Screening Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Repositioning of DHFR Inhibitors
Current Topics in Medicinal Chemistry Proteomics for Transthyretin (TTR) Related Amyloidosis
Current Proteomics Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers
Current Medicinal Chemistry Current Bioactive Azole-Containing Natural Products
Current Bioactive Compounds Computational Methods for Protein-Protein Interaction and their Application
Current Protein & Peptide Science Helicobacter pylori: An Overview on Antimicrobials and Drug Delivery Systems for its Eradication
Current Drug Delivery Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism Methods for Docking Small Molecules to Macromolecules: A User’s Perspective. 2. Applications
Current Pharmaceutical Design Mechanism(s) Involved in Opioid Drug Abuse Modulation of HAND
Current HIV Research Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs
Current Pharmaceutical Design